An Additional Dose of Viral Vector COVID-19 Vaccine and mRNA COVID-19 Vaccine in Kidney Transplant Recipients: A Randomized Controlled Trial

An Immunogenicity study of An Additional Dose of COVID-19 Vaccine in Kidney Transplant Recipients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211102003

Enrollment

120

Registered

2021-11-02

Start date

2021-11-22

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult KT recipients immunosuppression immunogenicity safety COVID-19

Interventions

All adult kidney transplant recipients who were fully vaccinated with SARS-CoV-2 vaccine however with inadequate immune response will be randomly offered for mRNA vaccine,All adult kidney transplant r

Active Comparator Other,Active Comparator Other

mRNA-based vaccine,Viral-vectored vaccine

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: All adult kidney transplant recipients who were fully vaccinated with SARS-CoV-2 vaccine however with inadequate immune response

Exclusion criteria

Exclusion criteria: Declined to participate Allergic to vaccine given

Design outcomes

Primary

Measure	Time frame
Immunogenicity Week 0 and week 2 Check Humoral and cell-mediated immunity prior to additional dose of vaccine and 2 weeks after	—

Secondary

Measure	Time frame
Safety Day 3 and day 7 Solicited and unsolicited adverse events at day 3 and day 7 after additional dose of vaccine	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital

jackrapong.brm@mahidol.ac.th022011581

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026